AI-guided Prognostication and Cranial Radiotherapy Optimization in EGFR-TKI-treated Non-small Cell Lung Cancer Patients With Baseline Brain Metastases

This study uses artificial intelligence to help predict outcomes and guide radiation treatment decisions for people with advanced non-small cell lung cancer (NSCLC) that has spread to the brain. Participants have a specific genetic mutation (EGFR) and are being treated with targeted therapy pills called EGFR-TKIs. **You may be eligible if...** - You are 18 years or older - You have been diagnosed with stage IV non-small cell lung cancer - Your tumor has an EGFR L858R or exon 19 deletion mutation - You had brain metastases (cancer spread to the brain) at the time of diagnosis - You are currently receiving or have received third-generation EGFR-TKI treatment - You had a complete imaging workup including a brain MRI before starting treatment - You have a good performance level (able to care for yourself) **You may NOT be eligible if...** - You have multiple different primary cancers (unless a skin cancer or cervical cancer that was fully treated more than 5 years ago) - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.